Showing results (831-840 of 896) with videos related to

Sort By:
Pageof 90
Bioorganic & Medicinal Chemistry Letters|November 10, 2009
Hit to lead studies on (hetero)arylpyrimidines--agonists of the canonical Wnt-beta-catenin cellular messaging systemAdam M Gilbert, Matthew G Bursavich, Nippa Alon, et al.
Angiogenesis|December 2, 2022
Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergyPatrycja Nowak-Sliwinska, Judy R van Beijnum, Christian J Griffioen, et al.
Urologic Oncology|February 23, 2013
Predictive factors of chronic kidney disease stage V after partial nephrectomy in a solitary kidney: a multi-institutional studyG Verhoest, J J Patard, E Oger, et al.
Technology and Health Care : Official Journal of the European Society for Engineering and Medicine|January 15, 2023
HPC+ in the medical field: Overview and current examplesMiriam Koch, Claudio Arlandini, Gregory Antonopoulos, et al.
Clinical Genitourinary Cancer|December 15, 2020
Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive MarkersSaskia Lisa Verhaart, Yasmin Abu-Ghanem, Sasja F Mulder, et al.
Contemporary Clinical Trials|September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma settingAngela Meade, Bhavna Oza, Eleni Frangou, et al.
Contemporary Clinical Trials|September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapseBhavna Oza, Eleni Frangou, Ben Smith, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 16, 2011
Osteogenic effects of a potent Src-over-Abl-selective kinase inhibitor in the mouseRichard J Murrills, Shoichi Fukayama, Frank Boschelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 TrialRobert J Motzer, Axel Bex, Paul Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancerKevin Sharpe, Grant D Stewart, Alan Mackay, et al.
Pageof 90